Shanda Asset Management Holdings’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.2M Hold
200,000
0.55% 6
2025
Q4
$5.9M Buy
200,000
+100,000
+100% +$2.72M 0.28% 9
2025
Q3
$2.58M Buy
+100,000
New +$2.79M 0.13% 7
2021
Q4
Sell
-41,500
Closed -$16M 54
2021
Q3
$16M Sell
41,500
-8,500
-17% -$3.13M 1.66% 17
2021
Q2
$11.7M Hold
50,000
0.96% 27
2021
Q1
$6.55M Buy
+50,000
New +$7.25M 0.54% 38

Other funds holding MRNA

Shanda Asset Management Holdings's MRNA Position: Q1 2026 in Review

Shanda Asset Management Holdings sold out of Moderna (MRNA) in Q1 2026, closing a stake of 300,000 shares — an estimated $14M sold.

Shanda Asset Management Holdings first reported a position in MRNA in Q2 2020 and held it in 3 quarters. The position peaked at $28.4M in Q1 2025. 723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Shanda Asset Management Holdings reported no remaining Moderna position as of Q1 2026 after selling out during the quarter.
  • Shanda Asset Management Holdings sold 300,000 Moderna shares in Q1 2026, an estimated $14M.
  • Shanda Asset Management Holdings first reported a position in Moderna in Q2 2020 and held it in 3 quarters.
  • Shanda Asset Management Holdings's Moderna position peaked at $28.4M in Q1 2025.
  • 723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Shanda Asset Management Holdings's 13F filing for Q1 2026, filed 15 May 2026.